Synektik Sa · GPW:SNT
Synektik Sa — Q1 FY2024 Earnings Presentation
21 slides from Synektik Sa's earnings presentation, February 2025
Slide 1: Investor Presentation Q1 FY2024
SYNEKTIK SA Investor Presentation Q1 2024 FY February 2025 Q1 FY 2024 Financial results | Investor presentation 1
Slide 2: Synektik in snapshot
Synektik in snapshot WIG, mWIG40, Indexes WIGTECH, WIG-Poland ISIN PLSNKTK0001 203m 51m Number of shares 8 529 129 PLN PLN Capitalisation(1) PLN 1.97bn REVENUE FROM SALES, AJDUSTED EBITDA Enterprise value(2) PLN 1.81bn Q1 FY2024 Q1 FY2024 P/E(3) 18.9 EV/EBITDA(4) 12.6 Company profile Dividend yield
Slide 3: Highlights of Q1 FY2024
Highlights of Q1 FY2024 Sales of equipment and IT solutions – growing recurring revenues ▪ 191.1 million PLN in revenue (excluding intra-group transactions) in Q1 FY 2024, including 68 million PLN in recurring revenue (62% YoY growth). ▪ Expansion into the Baltic countries; establishment of Synektik
Slide 4: Financial performance in Q1 FY2024
Financial performance in Q1 FY2024 ▪ 191.1 million PLN in revenue from the sale of equipment, IT solutions, and Consolidated revenue (PLN million) service provision (excluding intra-group transactions), compared to 261.4 Q1 FY2024 203.1 million PLN in revenue in Q1 FY 2023 (which was achieved due to
Slide 5: Group's adjusted EBITDA in FY 2021-2024
Group’s adjusted EBITDA in FY 2021-2024 Adjusted EBITDA EBITDA growth driven by: 53.1 51.0 (PLNm) ▪ increase in sales of equipment used in therapy 32.4 34.5 29.8 31.7 25.5 24.9 ▪ growing scale of recurring sales in both 13.3 segments 10.9 5.5 6.2 7.1 ▪ impact of operating leverage achieved Q1 2021 Q
Slide 6: Group's recurring sales in FY 2021-2024
Group’s recurring sales in FY 2021-2024 Recurring revenue for past 4 quarters Dynamic growth of recurring revenue (PLNm) Drivers: 31.9 ▪ Dynamically increasing demand for consumable parts and accessories for therapy equipment sold 31.5 by the Synektik Group Revenue from sales of radiopharmaceuticals
Slide 7: Selected financial data
Selected financial data PLN 000s Q1 FY 2024 Q1 FY 2023 Sales revenue 203 128 271 296 ▪ Cash surplus over financial liabilities amounting to EBIT 41 456 45 367 nearly 167 milion PLN as of December 31, 2024, EBIT margin 20% 17% securing financial needs and enabling a record 70.4 Adjusted EBITDA 51 022
Slide 8: Medical equipment and IT solutions
SYNEKTIK SA Medical equipment and IT solutions Q1 FY 2024 Financial results | Investor presentation 8
Slide 9: Medical equipment and IT solutions: Key information
Medical equipment and IT solutions Key information Synektik is a leading provider of medical equipment and IT solutions used in radiology, oncology, cardiology and neurology Core areas: ▪ Sale of medical equipment from several leading manufacturers, used in radiology, therapy and nuclear medicine ▪
Slide 10: Medical equipment and IT solutions: Financial results
Medical equipment and IT solutions Financial results (million PLN ) Growing business profitabiity 261.4 ▪ 191.1 million PLN in revenue in Q1 FY 2024, compared to 261.4 million PLN the year 191.1 before. ▪ 50.6 million PLN EBITDA in Q1 FY 2024; increase in EBITDA segment profitability by 53.1 50.6 6.
Slide 11: Sales of medical equipment, orders for implementation
Medical equipment and IT solutions Sales of medical equipment, orders for implementation Promising prospects for the coming quarters and active offers (in million PLN) ▪ Secured orders worth 114 million PLN in Q1 FY 2024 219.2 ▪ The value of active offers as of the end of December 2024 is 123.4 mill
Slide 12: Commercialization of Da Vinci system
Medical equipment and IT solutions Commercialization of Da Vinci system Da Vinci assisted surgical procedures in Poland, Czech Republic and Slovakia 96 8000 (number) 7000 ▪ Approximately 4.1 thousand surgeries with the assistance of Da Vinci in Q1 FY 2024 in Poland (up 93% y/y), 13.8 thousand 6000 i
Slide 13: Da Vinci systems serviced by Synektik
Medical equipment and IT solutions Gdynia Da Vinci serviced by GK Synektik Słupsk Gdańsk Olsztyn 65 Białystok 96 Szczecin Bydgoszcz Toruń Wieliszew Biała Podlaska Grodzisk Da Vinci systems serviced da Vinci systems Gorzów Wlkp. Maz. by GK Synektik in Poland* Poznań Warszawa Siedlce Zielona Góra Lesz
Slide 14: Strengthening the Group's IT business
Medical equipment and IT solutions Strengthening the Group's IT business IT4KAN – completed IT installations • RIS/PACS ▪ Acquisition of 100% of shares in IT4KAN Sp. z o.o., a company • iDose specializing in the implementation and integration of IT systems in medicine and the distribution of medical
Slide 15: Radiopharmaceuticals
SYNEKTIK SA Radiopharmaceuticals Q1 FY 2024 Financial results | Investor presentation 15
Slide 16: Radiopharmaceuticals: Key information
Radiopharmaceuticals Key information ▪ Synektik is the largest producer and supplier of PET/CT radiopharmaceuticals in Poland 50+ Number of 3 Production sites together employees with R&D Centre ▪ Major producer of special radiopharmaceuticals Location of cyclotrons for the production of radiopharmac
Slide 17: Radiopharmaceuticals: Financial results
Radiopharmaceuticals Financial results (million PLN ) Growing revenues 12.1 9.9 ▪ 22% increase in sales (year-over-year) in Q1 FY 2024, up to 12.1 million PLN ▪ 88% increase in supplementary assortment sales, up to 3.8 million PLN. 4.1 3.9 ▪ 15% increase in sales of special markers, up to 2.5 millio
Slide 18: Cardiotracer
SYNEKTIK SA Cardiotracer Q1 FY 2024 Financial results | Investor presentation 18
Slide 19: Cardiotracer
Cardiotracer ▪ Preparations for the launch of a multi-center Phase III clinical trial in the United States. ▪ Technology transfer in progress, completed deliveries and installation of modules for the production of the cardio-tracer along with technology transfer documentation. [1] [2] [3] [4] APPROV
Slide 20: Q&A Session
SYNEKTIK SA Q&A SESSION Q1 FY 2024 Financial results | Investor presentation 20
Slide 21: Thank You!
Cezary Kozanecki Thank You! President of the Management Board, CEO ckozanecki@synektik.com.pl Dariusz Korecki Vice-President of the Management Board, CFO dkorecki@synektik.com.pl